296 related articles for article (PubMed ID: 23458390)
1. Risk of acute postoperative hypertension after topical photodynamic therapy for non-melanoma skin cancer.
Borroni RG; Carugno A; Rivetti N; Arbustini E; Brazzelli V
Photodermatol Photoimmunol Photomed; 2013 Apr; 29(2):73-7. PubMed ID: 23458390
[TBL] [Abstract][Full Text] [Related]
2. Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
Fai D; Arpaia N; Romano I; Vestita M; Cassano N; Vena GA
G Ital Dermatol Venereol; 2009 Jun; 144(3):281-5. PubMed ID: 19528909
[TBL] [Abstract][Full Text] [Related]
3. Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?
Ibbotson SH; Valentine R; Hearn R
Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):272-3. PubMed ID: 22971196
[TBL] [Abstract][Full Text] [Related]
4. Methyl aminolevulinate: actinic keratoses and Bowen's disease.
Morton CA
Dermatol Clin; 2007 Jan; 25(1):81-7. PubMed ID: 17126745
[TBL] [Abstract][Full Text] [Related]
5. The France-PDT study: a national prospective observational cohort survey on the use of methyl-aminolevulinate photodynamic therapy in France, with up to 6-month follow-up.
Farhi D; Bedane C; Savary J; Basset-Seguin N
Eur J Dermatol; 2013; 23(1):68-76. PubMed ID: 23400280
[TBL] [Abstract][Full Text] [Related]
6. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
Tyrrell JS; Campbell SM; Curnow A
Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting pain and effect of oral analgesia in topical photodynamic therapy.
Hambly RA; Mansoor N; Quinlan C; Shah Z; Lenane P; Ralph N; Moloney FJ
Photodermatol Photoimmunol Photomed; 2017 May; 33(3):176-179. PubMed ID: 28196277
[No Abstract] [Full Text] [Related]
8. Photodynamic therapy of non-melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid.
Gaál M; Otrosinka S; Baltás E; Ocsai H; Oláh J; Kemény L; Gyulai R
Acta Derm Venereol; 2012 Mar; 92(2):173-5. PubMed ID: 22113788
[No Abstract] [Full Text] [Related]
9. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma.
Morton CA; Szeimies RM; Sidoroff A; Braathen LR
J Eur Acad Dermatol Venereol; 2013 May; 27(5):536-44. PubMed ID: 23181594
[TBL] [Abstract][Full Text] [Related]
10. Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers.
Ortiz-Policarpio B; Lui H
Skin Therapy Lett; 2009; 14(6):1-3. PubMed ID: 19609473
[TBL] [Abstract][Full Text] [Related]
11. Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
Blake E; Allen J; Thorn C; Shore A; Curnow A
Lasers Med Sci; 2013 May; 28(3):997-1005. PubMed ID: 22926533
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
13. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
Aguilar M; de Troya M; Martin L; Benítez N; González M
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
[TBL] [Abstract][Full Text] [Related]
14. Methyl aminolaevulinate-photodynamic therapy for actinic keratoses, squamous cell carcinoma in situ and superficial basal cell carcinoma employing a square wave intense pulsed light device for photoactivation.
Downs AM; Bower CB; Oliver DA; Stone CA
Br J Dermatol; 2009 Jul; 161(1):189-90. PubMed ID: 19416229
[No Abstract] [Full Text] [Related]
15. [PDT panoramic view. Principle, photosensitizers, light sources and validated indications in dermatology].
Basset-Seguin N
Ann Dermatol Venereol; 2013 Nov; 140 Suppl 2():223-8. PubMed ID: 24199714
[TBL] [Abstract][Full Text] [Related]
16. Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions.
Themstrup L; Banzhaf CA; Mogensen M; Jemec GB
Photodiagnosis Photodyn Ther; 2014 Mar; 11(1):7-12. PubMed ID: 24280439
[TBL] [Abstract][Full Text] [Related]
17. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer.
Lehmann P
Br J Dermatol; 2007 May; 156(5):793-801. PubMed ID: 17419691
[TBL] [Abstract][Full Text] [Related]
18. Current methods for photodynamic therapy in the US: comparison of MAL/PDT and ALA/PDT.
Lee PK; Kloser A
J Drugs Dermatol; 2013 Aug; 12(8):925-30. PubMed ID: 23986167
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma.
Dijkstra AT; Majoie IM; van Dongen JW; van Weelden H; van Vloten WA
J Eur Acad Dermatol Venereol; 2001 Nov; 15(6):550-4. PubMed ID: 11843215
[TBL] [Abstract][Full Text] [Related]
20. Topical photodynamic therapy with porphyrin precursors--assessment of treatment-associated pain in a retrospective study.
Steinbauer JM; Schreml S; Babilas P; Zeman F; Karrer S; Landthaler M; Szeimies RM
Photochem Photobiol Sci; 2009 Aug; 8(8):1111-6. PubMed ID: 19639112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
